|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Investments: | ||||||||||||||||||||
| Fixed maturity securities available-for-sale, at estimated fair value (amortized cost: $4,441 and $4,464, respectively; allowance for credit losses of $0 and $0, respectively) | ||||||||||||||||||||
| Equity Securities, FV-NI | ||||||||||||||||||||
| Mortgage loans (net of allowance for credit losses of $4 and $2, respectively) | ||||||||||||||||||||
| Short-term investments, principally at estimated fair value | ||||||||||||||||||||
| Other invested assets, principally at estimated fair value | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accrued investment income | ||||||||||||||||||||
| Premiums, reinsurance and other receivables | ||||||||||||||||||||
| Deferred policy acquisition costs | ||||||||||||||||||||
| Current income tax recoverable | ||||||||||||||||||||
| Deferred income tax asset | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Separate account assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Equity | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Future policy benefits | ||||||||||||||||||||
| Policyholder account balances | ||||||||||||||||||||
| Other policy-related balances | ||||||||||||||||||||
| Payables for collateral under derivative transactions | ||||||||||||||||||||
| Short-term Debt | ||||||||||||||||||||
| Current income tax payable | ||||||||||||||||||||
| Deferred income tax liability | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Separate account liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholder’s Equity | ||||||||||||||||||||
| Common stock, par value $10 per share; 200,000 shares authorized, issued and outstanding | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings (deficit) | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Total stockholder’s equity | ||||||||||||||||||||
| Total liabilities and stockholder’s equity | ||||||||||||||||||||
Loading...
